

FOI REF: 21/261

01st June 2021

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

I am analysing the usage of anti-VEGF treatments for eye conditions. I would greatly appreciate if you could answer the below questions:

- 1. For the 4-month period from January to April 2021, how many patients has your trust treated with the following anti-VEGF treatments:**

• Aflibercept (Eylea)	2717
• Bevacizumab (Avastin)	119
• Brolucizumab	0
• Dexamethasone (Ozurdex)	31
• Fluocinolone acetonide (Iluvien)	0
• Ranibizumab (Lucentis)	865

- 2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.**

• Aflibercept (Eylea)	208
• Bevacizumab (Avastin)	28
• Brolucizumab	0
• Dexamethasone (Ozurdex)	1
• Fluocinolone acetonide (Iluvien)	0
• Ranibizumab (Lucentis)	158

3. Within your trust, how many intra-vitreous injections/implants of each the following treatments have been used (for any eye condition) in the four-month period from January to April 2021:

• Aflibercept (Eylea)	2717
• Bevacizumab (Avastin)	119
• Brolucizumab	0
• Dexamethasone (Ozurdex)	31
• Fluocinolone acetonide (Iluvien)	0
• Ranibizumab (Lucentis)	865

4. If your trust is able to identify intra-vitreous injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from January to April 2021 for each of the following conditions: Diabetic Macular Oedema (DMO)

• Aflibercept (Eylea)	233
• Bevacizumab (Avastin)	14
• Dexamethasone (Ozurdex)	8
• Ranibizumab (Lucentis)	111

Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO)

• Aflibercept (Eylea)	319
• Bevacizumab (Avastin)	5
• Dexamethasone (Ozurdex)	20
• Ranibizumab (Lucentis)	232

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, please write to the Freedom of Information Department, esh-tr.foi@nhs.net, quoting the above reference.

Yours sincerely

Linda Thornhill (Mrs)
Corporate Governance Manager
esh-tr.foi@nhs.net